U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 31 results

Status:
US Approved Rx (2018)
First approved in 2018

Class (Stereo):
CHEMICAL (ACHIRAL)



Avatrombopag is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in increased production of platelets. Avatrom...
Status:
US Approved Rx (2007)
First approved in 2005

Class (Stereo):
CHEMICAL (ACHIRAL)



Conivaptan is an arginine vasopressin (AVP) receptor antagonist with affinity for AVP receptor subtypes V1A and V2. The antidiuretic action of AVP is mediated through activation of the V2 receptor, which functions to regulate water and electrolyte ba...
Status:
US Approved Rx (2019)
First approved in 2004

Class (Stereo):
CHEMICAL (ABSOLUTE)



Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of ...
Status:
US Approved Rx (2024)
First approved in 1988

Class (Stereo):
CHEMICAL (RACEMIC)



Nicardipine is a potent calcium channel blockader with marked vasodilator action used to treat high blood pressure and angina. By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the...
Status:
US Approved Rx (2007)
First approved in 1985

Class (Stereo):
CHEMICAL (EPIMERIC-AXIAL)



Cefotetan is a semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positi...
Status:
Other

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

YM022 is an extremely potent and highly selective gastrin/cholecystokinin (CCK)-B receptor antagonist. It was discovered, that this compound possesses antisecretory and antiulcer activities in rats and that it represents a useful therapeutic agent in...
Status:
Possibly Marketed Outside US
First approved in 2023

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Amosulalol is a beta- and alpha-1 adrenoceptor-blocking agent developed for the treatment of hypertension. Amosulalol does not cross blood brain barrier and does not have adverse affect on CNS system.The drug is marketed under the name Lowgan in Japa...
Status:
Possibly Marketed Outside US
First approved in 2011

Class (Stereo):
CHEMICAL (RACEMIC)



Indeloxazine is a neuroleptic, originally developed and marketed in Japan. It is indicated to allay autonomic hyperactivity following cerebral infarction, cerebral haemorrhage or atherosclerosis. It was found to be a weak inhibitor of both type A and...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Bamidipine is an antihypertensive drug belonging to the dihydropyridine (DHP) group of calcium antagonists. The product was originally developed by Yamanouchi Pharmaceutical (Tokyo, Japan) and is currently marketed in Japan under the trade name of Hy...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (RACEMIC)



3-ISOPROPYLAMINO-1,2-PROPANEDIOL (Indenolol) is an antihypertensive agent, whose beta 1-adrenoceptor antagonist properties combined with beta 2-adrenoceptor agonist properties have been shown by experimental studies in animals. It was used for the tr...